Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Most people notice changes in their appetite within the first two weeks
These include uncertainties regarding optimal treatment duration, management of side effects, and the high cost associated with these medications
Neoplasma 62 (2), 199208
Highlights: Retatrutide helped participants lose up to 30% of their body weight , around 85 pounds The drug mimics both GLP-1 and glucagon , making it a triple agonist Retatrutide showed stronger weight reduction than Wegovy and Zepbound in longer trials helped participants lose up to 30 percent of their body weight during clinical trials (1 Trusted Source Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial Go to source)
This may include Ozempic/wegovy at the lowest effective dose superimposed with either phentermine/phendimetrazine, Wellbutrin, naltrexone
They also recently expanded into longevity treatments including NAD+ and sermorelin, though GLP-1 medications remain their bread and butter
